Conatus sinks after NASH therapy misses fibrosis endpoint

Conatus lost $1.49 (51%) to $1.42 in after-hours trading Thursday after reporting that emricasan missed the primary endpoint in the Phase IIb ENCORE-NF to treat non-alcoholic

Read the full 266 word article

User Sign In